Phaseline

Targets › TNKS

TNKS (Poly [ADP-ribose] polymerase tankyrase-1): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 1 Phase 1, 1 Phase 2; Metabolic and endocrine, Oncology; next expected readout Mar 2027.

Poly-ADP-ribosyltransferase involved in various processes such as Wnt signaling pathway, necroptosis, telomere length and vesicle trafficking. Acts as an activator of the Wnt signaling pathway by mediating poly-ADP-ribosylation (PARsylation) of AXIN1 and AXIN2, 2 key components of the beta-catenin destruction complex: poly-ADP-ribosylated target proteins are recognized by RNF146, which mediates their ubiquitination…. (UniProt, O95271)

Open in Phaseline: the race on TNKS, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Allarity Therapeutics2X-121
Poly [ADP-ribose] polymerase-1 inhibitor; Poly [ADP-ribose] polymerase 2 inhibitor; Tankyrase 1/2 inhibitor
PARP1, PARP2, TNKS2, TNKSPhase 2Advanced Ovarian CancerMar 2027
ElucidermELU42
Tankyrase inhibitor combined with derivatized hyaluronic acid (DHA77) excipient for topica
TNKSPhase 1Diabetic Foot Ulcer–

Conditions

Diabetic Foot Ulcer (1) Advanced Ovarian Cancer (1)

Modalities

small molecule (2)

Companies

Eluciderm (1) Allarity Therapeutics (1)

Related targets

PARP1 (1) PARP2 (1) TNKS2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.